Publications by authors named "Greer Dan"

Claim this Profile
I
Impact on direct and indirect costs of switching patients with inflammatory bowel disease from intravenous to subcutaneous infliximab (CT-P13).
Isabel Carbery, Gemma Burdge, Tanya Clark, Giacomo Broglio, Dan Greer

BMJ Open Gastroenterol· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Uptake of a Switching Program for Patients Receiving Intravenous Infliximab and Vedolizumab to Subcutaneous Preparations.
Gemma Burdge, Alice Hardman, Isabel Carbery, Giacomo Broglio, Dan Greer

J Clin Med· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy, tolerability, and predictors of response to infliximab therapy for Crohn's disease: a large single centre experience.
Michael B Sprakes, Alexander C Ford, Lisa Warren, Dan Greer, John Hamlin

J Crohns Colitis· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adalimumab as second line anti-tumour necrosis factor alpha therapy for Crohn's disease: A single centre experience.
Michael B Sprakes, P John Hamlin, Lisa Warren, Dan Greer, Alexander C Ford

J Crohns Colitis· August 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Accelerated infliximab infusions are safe and well tolerated in patients with inflammatory bowel disease.
Donnellan F Clare, Ford C Alexander, Sprakes Mike, Greer Dan, Fairclough Allan

Eur J Gastroenterol Hepatol· January 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis